» Articles » PMID: 35584094

Factors Affecting Prolonged Time to Extubation in Patients Given Remimazolam

Overview
Journal PLoS One
Date 2022 May 18
PMID 35584094
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To analyze the cause of prolonged recovery from general anesthesia with remimazolam.

Methods: We studied 65 patients under general anesthesia with remimazolam. According to time to extubation, patients were divided into short period (SP) (n = 34, < 15 min) and long period (LP) (n = 31, ≥ 15 min) groups. Variables affecting time to extubation such as age, sex, height, body weight, body mass index (BMI), plasma albumin concentration, ASA class, duration of surgery, and total duration of general anesthesia, and total dose of remimazolam were compared between SP and LP groups. At the end of remimazolam infusion and upon extubation, predictive remimazolam concentrations were calculated using pharmacokinetic/pharmacodynamic three compartment modeling.

Results: LP group showed significantly higher BMI, older age, and lower plasma albumin concentration compared with those of SP group. Logistic regression analysis showed that the probability of time to extubation of ≥ 15 min was higher in patients with BMI greater than 22.0 kg/m2 (AUC 0.668, 95% CI 0.533‒0.803), ages older than 79.0 years (AUC 0.662, 95% CI 0.526‒0.798), and plasma albumin concentrations lower than 3.60 g/dl (AUC 0.720, 95% CI 0.593‒0.847). LP group showed significantly lower predicted remimazolam concentration than SP group upon extubation despite no difference in concentration between both groups at the end of infusion. Pharmacological analysis estimates that LP group is more sensitive to remimazolam than SP group through amplified responses.

Conclusions: Lower remimazolam doses should be considered for the overweight patients, elderly, and those with lower plasma albumin concentration.

Citing Articles

Effect-Site Concentration of Remimazolam by Age Groups During Target-Controlled Infusion for Total Intravenous Anesthesia: A Retrospective Comparative Study.

Park J, Seo K, Kwak J, Baek H Drug Des Devel Ther. 2024; 18:5149-5159.

PMID: 39554758 PMC: 11568852. DOI: 10.2147/DDDT.S480734.


Age-Related Response to Remimazolam among Older Patients Undergoing Orthopedic Surgery: A Single-Center Prospective Observational Study.

Chae M, Lee N, Koh H Medicina (Kaunas). 2024; 60(10).

PMID: 39459403 PMC: 11509805. DOI: 10.3390/medicina60101616.


Remimazolam and Its Place in the Current Landscape of Procedural Sedation and General Anesthesia.

Brohan M, Brohan J, Goudra B J Clin Med. 2024; 13(15).

PMID: 39124629 PMC: 11312559. DOI: 10.3390/jcm13154362.


Remimazolam-Induced Anaphylaxis and Cardiovascular Collapse: A Narrative Systematic Review of Eleven Cases.

Lee J, Kim S Medicina (Kaunas). 2024; 60(6).

PMID: 38929588 PMC: 11205925. DOI: 10.3390/medicina60060971.


Relationship between age and remimazolam dose required for inducing loss of consciousness in older surgical patients.

Song J, Wang X, Fu X, Chen W, Tang S, Deng F Front Med (Lausanne). 2024; 11:1331103.

PMID: 38741769 PMC: 11089116. DOI: 10.3389/fmed.2024.1331103.


References
1.
Wanderer J, Nelson S, Hester D, Shotwell M, Sandberg W, Anderson-Dam J . Sources of Variation in Anesthetic Drug Costs. Anesth Analg. 2017; 126(4):1241-1248. DOI: 10.1213/ANE.0000000000002732. View

2.
Bertz R, Kroboth P, Kroboth F, Reynolds I, Salek F, Wright C . Alprazolam in young and elderly men: sensitivity and tolerance to psychomotor, sedative and memory effects. J Pharmacol Exp Ther. 1997; 281(3):1317-29. View

3.
Vinik H, Bradley Jr E, Kissin I . Midazolam-alfentanil synergism for anesthetic induction in patients. Anesth Analg. 1989; 69(2):213-7. View

4.
Antonik L, Goldwater D, Kilpatrick G, Tilbrook G, Borkett K . A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics. Anesth Analg. 2011; 115(2):274-83. DOI: 10.1213/ANE.0b013e31823f0c28. View

5.
Zhou J, Leonowens C, Ivaturi V, Lohmer L, Curd L, Ossig J . Population pharmacokinetic/pharmacodynamic modeling for remimazolam in the induction and maintenance of general anesthesia in healthy subjects and in surgical subjects. J Clin Anesth. 2020; 66:109899. DOI: 10.1016/j.jclinane.2020.109899. View